Melanoma success validates the INT concept; RCC becomes the next key test

Overview

This report summarizes key takeaways from Barclays hosting Moderna management for a non-deal roadshow in New York, focusing on the Phase 3 melanoma results for the personalized neoantigen therapy intismeran autogene, subsequent readouts in indications including renal cell carcinoma, mechanism of action, capacity and costs, and the competitive barriers created by algorithms and proprietary data. The report views the melanoma success as a key positive but maintains an Equal Weight rating.

Core views

The personalized neoantigen therapy intismeran autogene (INT), jointly developed by Moderna and Merck and combined with Keytruda, met both the recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) endpoints at the first interim analysis of a Phase 3 adjuvant melanoma trial. The press release described the improvements as statistically significant and clinically meaningful, but the hazard ratio (HR) has not yet been disclosed. Barclays believes this represents important proof of concept for using mRNA technology in oncology and for personalized mRNA medicine, and marks the first time a treatment regimen has demonstrated a benefit over Keytruda in the adjuvant melanoma setting. Following the August 19 data release, Moderna shares rose approximately 177%, compared with an approximately 6% increase in the XBI over the same period; the shares subsequently declined approximately 17% from August 20 to 21, while the XBI fell approximately 2%. The next key information will be the full HR and subgroup analyses, expected to be presented at an international medical conference in the fall. The report speculates that this could be ESMO, held from October 23 to 26. Investors hope the HR will be closer to 0.7, which would help assess INT's probability of success in other tumors. The subsequent clinical focus is shifting more toward renal cell carcinoma (RCC) than muscle-invasive bladder cancer (MIBC). The latter-stage Phase 2 RCC trial uses a randomized, blinded, event-driven design and enrolled 300 patients, with enrollment completed since the second quarter of 2025. Management stated that the first interim data could be available in late 2026 or could be delayed until early 2027. A longer time to readout would imply fewer events and could correspond to a stronger event-reduction effect, which would actually increase management's confidence. The trial also includes a final analysis and may have additional interim analyses, although the specific arrangements have not been disclosed. The RCC trial could potentially support registration. Drawing on experience from the previous latter-stage Phase 2 melanoma trial, Moderna doubled the size of the RCC trial and can adjust the statistical analysis plan while maintaining the blind to increase the probability of registrational success. Enrollment in the latter-stage Phase 2 MIBC trial has also been completed, and its readout timing could be close to that of RCC. However, management believes that changes in the MIBC treatment landscape mean the trial will be more informative in nature and is less likely to become a registrational study. Enrollment in the Phase 3 lung cancer trial is progressing well. Merck is primarily responsible for advancing the clinical study, and management views its execution capabilities as strong. Overall, management expects INT to generate a round of data readouts every 6 to 12 months over the next several years. Following the melanoma result, the key debate has shifted from whether the technology can work in cancer to which cancer types it can expand into. The main scientific question for RCC is whether INT can remain effective given that RCC generally has a lower tumor mutational burden and lower immunogenicity than melanoma. Management's mechanistic explanation is that the melanoma success indicates the principal constraint in tumor immunity may not necessarily be T-cell exhaustion; the more important factor is enhancing T-cell priming so that T cells can recognize and attack tumor cells. Management stated that, in the company's research, neither tumor mutational burden nor PD-1 status showed an association with differences in immunogenicity or efficacy. A T cell may need to recognize only one antigen to attack tumor cells presenting that antigen. Phase 2 translational research showed that, among seven patients without recurrence, recognition of all 34 antigens was unnecessary; the actual range recognized was 1 to 18. This suggests that after INT reaches a certain antigen-count threshold, the marginal benefit of adding more antigens may be limited. Based on this, Barclays believes INT may be effective across different tumor mutational burden levels, although the relevant subgroup results in the complete dataset remain important evidence for testing this view. On commercialization, management expressed strong confidence in preparations and supply capacity for the initial melanoma launch. INT has treated approximately 3,000 patients across 40 countries to date. The company believes its current clinical-stage operating scale has already reached the level required for the first several years following the melanoma launch. If additional indications succeed, four additional spaces within the existing manufacturing facility can be activated, with each capacity expansion taking approximately 12 months and requiring limited capital expenditure. Management stated that INT's cost of goods sold will be comparable to that of complex biologics and far below that of cell therapies, and believes the current scale and cost of clinical production are sufficient for the product to be profitable from the initial launch. Management also views INT's personalized algorithms and proprietary data as a potentially durable technological moat. Unlike conventional drugs, personalized therapies do not face an identical conventional patent-expiration model. Moderna can use protected clinical research data to continuously iterate the algorithms and software that generate INT. Unblinding the Phase 3 melanoma trial will provide a large volume of new proprietary data for further training and improving the algorithms. Management believes that even if competitors emerge in the future, the company's data, experience, and algorithmic iteration could keep INT technologically ahead for years. However, there is currently no established regulatory pathway for continuously updating personalized therapies and their generation software, and the company is still working with regulators to define the relevant requirements. Although market attention has clearly shifted toward the oncology business, Barclays continues to view the vaccine business as an important foundation for Moderna. Management noted that the conventional vaccine market requires large-scale studies and has high entry costs, but the company has successfully brought new technology into this oligopolistic market. Management expects the vaccine business to provide a larger share of the company's funding in the future for investment in oncology programs. The U.S. influenza vaccine was approved on August 5 and is expected to begin making a meaningful revenue contribution in the next influenza season. A broader vaccine portfolio should also help buffer annual fluctuations in demand for any single respiratory disease.

Analysis framework

Barclays first establishes the importance of the event using the first interim results from the Phase 3 melanoma trial and the subsequent share-price reaction, then combines information from the management roadshow to map out the trial progress and readout sequence for RCC, MIBC, and lung cancer. The report subsequently uses data on T-cell priming, tumor mutational burden, and antigen recognition to explain the scientific basis for expansion across cancer types, assesses commercialization readiness through the existing treatment scale, capacity expansion cycle, and cost of goods sold, and finally discusses algorithms, proprietary data, the regulatory pathway, and the vaccine business's role in supporting oncology investment.

Methodology notes

• Event-Driven Strategy and Behavioral FinanceEvent-driven analysis

  Clinical data and catalyst sequence analysis

  The report analyzes how different events—including the Phase 3 melanoma results, complete data in the fall, the first RCC readout, and subsequent clinical milestones every 6 to 12 months—could progressively change assessments of INT's probability of success across cancer types.

• Competition and Strategy FrameworkMoat / competitive advantage

  A technological moat formed by proprietary data and algorithmic iteration

  The report believes Moderna can use its continually expanding proprietary clinical data to update the algorithms that generate INT, making its competitive advantage not entirely dependent on conventional patent terms and potentially allowing it to retain a technological lead after competition emerges.

• (Out-of-vocabulary methodology)

  Clinical translation and biomarker mechanism analysis

  The report uses the T-cell priming mechanism, tumor mutational burden, PD-1 status, and the range of patient antigen recognition to discuss whether the melanoma results can be extrapolated to less immunogenic cancers such as RCC.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Moderna (MRNA)

  The Phase 3 melanoma success validated the potential of INT and personalized mRNA-based oncology treatment. Subsequent valuation will depend primarily on the complete data and whether success can be replicated in indications such as RCC.

  Strengths

  The melanoma trial met the RFS and DMFS endpoints; the company possesses proprietary clinical data and continuously iterable algorithms; its existing production scale can support the initial launch; and the vaccine business can provide a funding foundation for oncology R&D.

  Weaknesses

  The melanoma HR and subgroup data have not yet been disclosed; changes in the treatment landscape have reduced the potential registrational value of the MIBC trial; and there is no established regulatory pathway for personalized therapy software updates.

  Comparison

  The report states that this is the first treatment regimen to demonstrate a benefit over Keytruda in the adjuvant melanoma setting. INT's cost of goods sold is expected to be comparable to that of complex biologics and far below that of cell therapies.

  Risks

  RCC has a lower tumor mutational burden and lower immunogenicity than melanoma, so efficacy across cancer types still requires validation through clinical data, and the relevant regulatory framework has not yet been established.

Key data

• Phase 3 melanoma endpointsRFS and DMFS met at the first interim analysisINT combined with Keytruda versus Keytruda monotherapy; HR not yet disclosed
• HR watched by investorsClose to 0.7This is the level that investors hope to see according to the report, not a disclosed result
• Share-price performance after data releaseApproximately +177%Following the August 19 melanoma data release; XBI approximately +6% over the same period
• Subsequent share-price pullbackApproximately -17%August 20 to 21; XBI approximately -2% over the same period
• Latter-stage Phase 2 RCC trial sizen=300Randomized, blinded, and event-driven; enrollment completed since the second quarter of 2025
• Expected first RCC readoutLate 2026 to early 2027Readout timing may vary depending on the pace of event accumulation
• Frequency of subsequent INT readoutsEvery 6 to 12 monthsManagement expects a series of data readouts over the next several years
• Antigen recognition in Phase 2 translational research1 to 18, out of 34 designed antigensThe seven patients without recurrence did not need to recognize all 34 antigens
• Cumulative INT treatment scaleApproximately 3,000 patients across 40 countriesManagement believes the existing operating scale can support initial melanoma launch demand
• Additional manufacturing spaces4Each activation takes approximately 12 months and requires limited capital expenditure
• Price target$125Barclays updates its price target and maintains its Equal Weight rating
• Reference share priceUSD 145.13Closing price on August 21, 2026

Impact & implications

Barclays believes the Phase 3 melanoma success reduces the proof-of-concept risk for INT as an oncology treatment platform and shifts the market's focus toward its ability to replicate success across cancer types. If the full HR, subgroup analyses, and RCC data support management's views on T-cell priming and efficacy across mutational burden levels, the scope for expanding INT into additional indications will become clearer. At the same time, existing capacity, expandable manufacturing facilities, and a cost structure comparable to complex biologics provide a foundation for potential commercialization. Proprietary data-driven algorithmic iteration could extend the competitive advantage, although the corresponding regulatory pathway still needs to be established. The vaccine business is viewed as a funding foundation that can support oncology R&D investment and buffer fluctuations in respiratory disease demand.

Risks

• RCC generally has a lower tumor mutational burden and lower immunogenicity than melanoma, potentially making it more difficult for INT to replicate its success in this cancer type.
• The first RCC readout could be delayed from late 2026 to early 2027, with the timing dependent on the pace of event accumulation.
• Recent changes in the MIBC treatment landscape make its latter-stage Phase 2 trial more informative in nature and reduce its relevance as a registrational study.
• There is currently no established regulatory pathway for continuously updating personalized therapies and their generation software.

What to watch

• Watch for the complete melanoma HR and subgroup analyses to be presented at an international medical conference in the fall; the report speculates that disclosure could occur at ESMO from October 23 to 26.
• Watch the subgroup results across different tumor mutational burden levels in the melanoma data to assess whether INT can be effective across TMB levels.
• Watch for the first interim readout from the latter-stage Phase 2 RCC trial in late 2026 to early 2027 and its potential registrational pathway.
• Watch the contemporaneous data from the latter-stage Phase 2 MIBC trial and enrollment progress in the Phase 3 lung cancer trial.
• Watch capacity expansion, commercialization costs, and regulators' definition of the pathway for personalized therapy algorithm and software updates.